Spray-on skin developer Avita Medical is gearing up for the US launch of its RECELL technology with the purchase of a Californian factory.

Avita (ASX:AVH) is working to commercialise a technology called RECELL, which helps skin growth after burns or chronic wounds and reduces the amount of skin harvested during surgery. ReCell was originally developed by former Australian of the Year Fiona Woods.

Trial results released in April showed the treatment significantly reduced donor skin requirements and pain.

This morning the biotech told investors it would take over a Californian manufacturing site now managed by a Fortune 500 company that assembles the RECELL device.

The purchase comes as the company prepares to launch its tech in the coming year, with the Food and Drug Administration currently reviewing a pre-market approval application for the RECELL treatment.

Avita says FDA approval is on track for the third quarter of 2018, with the formal market launch to come in the months after.

The company’s share price is up 11 per cent this month, with investors responding positively to updates including a $16 million institutional placement completed in the first week of June.

Avita Medical (ASX:AVH) share price, past 12 months.

Stockhead has contacted the company for comment.